| Domains Pertaining to Strength of Evidence | Magnitude of Effect | Strength of Evidence | ||||
|---|---|---|---|---|---|---|
| Number of Studies; Number of Subjects | Risk of Bias; Design | Consistency | Directness | Precision | Mean, %, or Effect Size (ES) | High, Moderate, Low, Insufficient |
| PTSD Symptom Reduction: CAPS and PSS | Insufficient | |||||
| Fluoxetine vs. EMDR 1; 59 | Medium; RCT | Unknown (single study) | Direct | Imprecise | WMD −10.1 favoring fluoxetine, p=ns | Insufficient |
| Symptom Remission: | ||||||
| Fluoxetine vs. EMDR 1; 59 | Medium; RCT | Unknown (single study) | Direct | Imprecise | RD 0.15, p=ns | Insufficient |
| Loss of Diagnosis | ||||||
| Fluoxetine vs. EMDR 1; 59 (post) 1; 50 (f/up) | Medium; RCT | Unknown (single study) | Direct | Imprecise | RD 0.03 favoring EMDR, p=ns | Insufficient |
| Prevention/reduction of comorbid depression | ||||||
| Fluoxetine vs. EMDR 1; 59 (post) 1; 50 (f/up) | Medium; RCT | Unknown (single study) | Direct | Imprecise | WMD −1.9, p=ns favoring EMDR | Insufficient |
BDI = Beck Depression Inventory; CAPS = Clinician-Administered PTSD Scale – total; f/up, 6 month followup; NR = not reported; NS = non-significant; post = post-treatment; wk = week.
From: Appendix I, Strength of Evidence
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.